SINGAPORE PAINCARE HOLDINGS LIMITED

Company Registration No.:201843233N
(Incorporated in the Republic of Singapore)

UPDATE ON TRAINING REQUIREMENT FOR FIRST TIME DIRECTOR

The Board of Directors ("**Board**") of Singapore Paincare Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the announcement released on 08 April 2022 (the "**Previous Announcement**") in respect of the training which Dr. Lim Kah Meng ("**Dr. Lim**") needs to complete as a first-time director of a listed issuer.

Unless otherwise defined, all capitalised terms shall have the same meaning ascribed to them in the Previous Announcement.

The Board wishes to update that Dr. Lim has completed part of the Prescribed Training, being LED 1, LED 8 and LED – Environmental, Social and Governance Essentials. In respect of the remaining SID courses, being LED 2 to LED 7, Dr. Lim has registered for the aforementioned courses to be held in October 2022 and confirmed his commitment to complete his Prescribed Training by 31 October 2022.

By Order of the Board
Lee Mun Kam Bernard
Executive Director and Chief Executive Officer
29 July 2022

Singapore Paincare Holdings Limited (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 30 July 2020. The initial public offering of the Company was sponsored by Novus Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been prepared by the Company and reviewed by the Sponsor, in compliance with Rule 226(2)(b) of the SGX-ST Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.